Prognostic factors of paraneoplastic pemphigus

Archives of Dermatology

Volumn 148, Issue 10, 2012, Pages 1165-1172

  Leger, Sandy ^a   Picard, Damien ^a   Ingen Housz Oro, Saskia ^b   Arnault, Jean Philippe ^c   Aubin, François ^d   Carsuzaa, Francis ^e   Chaumentin, Gilles ^x   Chevrant Breton, Jacqueline ^f   Chosidow, Olivier ^b   Crickx, Béatrice ^g   D'incan, Michel ^h   Dandurand, Michel ⁱ   Debarbieux, Stéphane ^j   Delaporte, Emmanuel ^k   Dereure, Olivier ^l   Doutre, Marie Sylvie ^m   Guillet, Gérard ⁿ   Jullien, Denis ^o   Kupfer, Ingrid ^p   Lacour, Jean Philippe ^q   Leonard, Fabienne ^r   Lok, Catherine ^s   Machet, Laurent ^t   Martin, Ludovic ^u   Paul, Carle ^v   Pignon, Jean Michel ^w   Robert, Caroline ^c   Thomas, Luc ^j   Weiller, Pierre Jean ^y   Ferranti, Vincent ^a   Gilbert, Danièle ^a   Courville, Philippe ^a   Houivet, Estelle ^a   Benichou, Jacques ^a   Joly, Pascal ^a   more..

^a ROUEN UNIVERSITY HOSPITAL   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d UNIVERSITY HOSPITAL OF BESANÇON   (France)

^e Military Teaching Hospital Sainte Anne   (France)

^f RENNES UNIVERSITY HOSPITAL   (France)

^g BICHAT HOSPITAL   (France)

^h UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

ⁱ NÎMES UNIVERSITY HOSPITAL   (France)

^j CENTRE HOSPITALIER LYON SUD   (France)

^k LILLE UNIVERSITY HOSPITAL   (France)

^l MONTPELLIER UNIVERSITY HOSPITAL   (France)

^m HAUT LÉVÊQUE HOSPITAL   (France)

ⁿ POITIERS UNIVERSITY HOSPITAL   (France)

^o Lyon Edouard Flerriot University Hospital   (France)

^p Infectious Diseases and Haematology   (France)

^q UNIVERSITY HOSPITAL OF NICE   (France)

^r Clinique Courlancy   (France)

^s AMIENS UNIVERSITY HOSPITAL   (France)

^t UNIVERSITÉ DE TOURS   (France)

^u ANGERS UNIVERSITY HOSPITAL   (France)

^v CHU PURPAN   (France)

^w Dunkerque Hospital   (France)

^x Roanne Hospital   (France)

^y TIMONE HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; IMMUNOGLOBULIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; THALIDOMIDE;

ADULT; AGED; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG MEGADOSE; ERYTHEMA MULTIFORME; FATALITY; FEMALE; HUMAN; HUMAN TISSUE; INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARANEOPLASTIC PEMPHIGUS; PRIORITY JOURNAL; RAT; SKIN BIOPSY; SKIN DEFECT; SKIN NECROSIS; SURVIVAL RATE;

ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AUTOANTIBODIES; CARRIER PROTEINS; CYTOSKELETAL PROTEINS; DESMOPLAKINS; ERYTHEMA MULTIFORME; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MUCOUS MEMBRANE; MULTIVARIATE ANALYSIS; NEOPLASMS; NERVE TISSUE PROTEINS; PARANEOPLASTIC SYNDROMES; PEMPHIGUS; PLAKINS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN PRECURSORS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84867656704     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2012.1830     Document Type: Article

References (43)

1. Anhalt GJ, Kim SC, Stanley JR, et al. Paraneoplastic pemphigus: an autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med. 1990;323(25):1729-1735.
2. Joly P, Thomine E, Gilbert D, et al. Overlapping distribution of autoantibody specificities in paraneoplastic pemphigus and pemphigus vulgaris. J Invest Dermatol. 1994;103(1):65-72. (Pubitemid 24227573)
3. Horn TD, Anhalt GJ. Histologic features of paraneoplastic pemphigus. Arch Dermatol. 1992;128(8):1091-1095.
4. Anhalt GJ. Paraneoplastic pemphigus. Adv Dermatol. 1997;12:77-97.
5. Oursler JR, Labib RS, Ariss-Abdo L, Burke T, O'Keefe EJ, Anhalt GJ. Human autoantibodies against desmoplakins in paraneoplastic pemphigus. J Clin Invest. 1992;89(6):1775-1782.
6. Borradori L, Trüeb RM, Jaunin F, Limat A, Favre B, Saurat JH. Autoantibodies from a patient with paraneoplastic pemphigus bind periplakin, a novel member of the plakin family. J Invest Dermatol. 1998;111(2):338-340. (Pubitemid 28354727)
7. Schepens I, Jaunin F, Begre N, et al. The protease inhibitor alpha-2-macroglobulin-like-1 is the p170 antigen recognized by paraneoplastic pemphigus autoantibodies in human. PLoS One. 2010;5(8):e12250.
8. Lemon MA, Weston WL, Huff JC. Childhood paraneoplastic pemphigus associated with Castleman's tumour. Br J Dermatol. 1997;136(1):115-117. (Pubitemid 27016188)
9. Jansen T, Plewig G, Anhalt GJ. Paraneoplastic pemphigus with clinical features of erosive lichen planus associated with Castleman's tumor. Dermatology. 1995;190(3):245-250.
10. Kaplan I, Hodak E, Ackerman L, Mimouni D, Anhalt GJ, Calderon S. Neoplasms associated with paraneoplastic pemphigus: a review with emphasis on non-hematologic malignancy and oral mucosal manifestations. Oral Oncol. 2004;40(6):553-562. (Pubitemid 38452674)
11. Camisa C, Helm TN. Paraneoplastic pemphigus is a distinct neoplasia-induced autoimmune disease. Arch Dermatol. 1993;129(7):883-886. (Pubitemid 23206015)
12. Dega H, Laporte JL, Joly P, et al. Paraneoplastic pemphigus associated with Hodgkin's disease. Br J Dermatol. 1998;138(1):196-198. (Pubitemid 28077969)
13. Wang J, Zhu X, Li R, et al. Paraneoplastic pemphigus associated with Castleman tumor: a commonly reported subtype of paraneoplastic pemphigus in China. Arch Dermatol. 2005;141(10):1285-1293. (Pubitemid 41498927)
14. Barbetakis N, Samanidis G, Paliouras D, et al. Paraneoplastic pemphigus regression after thymoma resection. World J Surg Oncol. 2008;6:83.
15. Krunic AL, Kokai D, Bacetic B, et al. Retroperitoneal round-cell liposarcoma associated with paraneoplastic pemphigus presenting as lichen planus pemphigoides-like eruption. Int J Dermatol. 1997;36(7):526-529. (Pubitemid 27355967)
16. Schlesinger T, McCarron K, Camisa C, Anhalt G. Paraneoplastic pemphigus occurring in a patient with B-cell non-Hodgkin's lymphoma. Cutis. 1998;61(2):94-96. (Pubitemid 128472616)
17. Perniciaro C, Kuechle MK, Colón-Otero G, Raymond MG, Spear KL, Pittelkow MR. Paraneoplastic pemphigus: a case of prolonged survival. Mayo Clin Proc. 1994;69(9):851-855. (Pubitemid 24275729)
18. Herrada J, Phillips DK, Hebert AA, Cabanillas F, Jordon RE. A progressive blistering eruption in a patient with lymphoma: paraneoplastic pemphigus. Arch Dermatol. 1997;133(1):97-, 100-101.
19. Rodot S, Botcazou V, Lacour JP, et al. Paraneoplastic pemphigus: review of the literature, apropos of a case associated with chronic lymphoid leukemia. Rev Med Interne. 1995;16(12):938-943. (Pubitemid 26021101)
20. Mutasim DF, Pelc NJ, Anhalt GJ. Paraneoplastic pemphigus. Dermatol Clin. 1993;11(3):473-481. (Pubitemid 23229731)
21. Nousari HC, Deterding R, Wojtczack H, et al. The mechanism of respiratory failure in paraneoplastic pemphigus. N Engl J Med. 1999;340(18):1406-1410. (Pubitemid 29205404)
22. Fullerton SH, Woodley DT, Smoller BR, Anhalt GJ. Paraneoplastic pemphigus with autoantibody deposition in bronchial epithelium after autologous bone marrow transplantation. JAMA. 1992;267(11):1500-1502.
23. Camisa C, Helm TN, Liu YC, et al. Paraneoplastic pemphigus: a report of three cases including one long-term survivor. J Am Acad Dermatol. 1992;27(4):547-553.
24. Mascaró JM Jr, Ferrando J, Solé MT, et al. Paraneoplastic pemphigus: a case of long-term survival associated with systemic lupus erythematosus and polymyositis. Dermatology. 1999;199(1):63-66. (Pubitemid 29366792)
25. Nousari HC, Brodsky RA, Jones RJ, Grever MR, Anhalt GJ. Immunoablative high-dose cyclophosphamide without stem cell rescue in paraneoplastic pemphigus: report of a case and review of this new therapy for severe autoimmune disease. J Am Acad Dermatol. 1999;40(5, pt 1):750-754. (Pubitemid 29230363)
26. + follicular lymphoma-associated paraneoplastic pemphigus. Arch Dermatol. 2001;137(3):269-272.
27. Becker LR, Bastian BC, Wesselmann U, Karl S, Hamm H, Bröcker EB. Paraneoplastic pemphigus treated with dexamethasone/cyclophosphamide pulse therapy. Eur J Dermatol. 1998;8(8):551-553. (Pubitemid 29003219)
28. Heizmann M, Itin P, Wernli M, Borradori L, Bargetzi MJ. Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL. Am J Hematol. 2001;66(2):142-144. (Pubitemid 32096630)
29. Izaki S, Yoshizawa Y, Kitamura K, et al. Paraneoplastic pemphigus: potential therapeutic effect of plasmapheresis. Br J Dermatol. 1996;134(5):987-989. (Pubitemid 26150311)
30. Helou J, Allbritton J, Anhalt GJ. Accuracy of indirect immunofluorescence testing in the diagnosis of paraneoplastic pemphigus. J Am Acad Dermatol. 1995;32(3):441-447.
31. Joly P, Richard C, Gilbert D, et al. Sensitivity and specificity of clinical, histologic, and immunologic features in the diagnosis of paraneoplastic pemphigus. J Am Acad Dermatol. 2000;43(4):619-626.
32. Rosenbach M, Murrell DF, Bystryn JC, et al. Reliability and convergent validity of two outcome instruments for pemphigus. J Invest Dermatol. 2009;129(10):2404-2410.
33. Harman KE, Seed PT, Gratian MJ, Bhogal BS, Challacombe SJ, Black MM. The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels. Br J Dermatol. 2001;144(4):775-780. (Pubitemid 32374780)
34. Mouquet H, Drenovska K, Lartigue A, et al. Detection and characterization of anti-envoplakin linker autoantibodies in paraneoplastic pemphigus using specific bead-based assay. Clin Immunol. 2008;129(2):304-312.
35. Ohyama M, Amagai M, Hashimoto T, Nousari HC, Anhalt GJ, Nishikawa T. Clinical phenotype and anti-desmoglein autoantibody profile in paraneoplastic pemphigus. J Am Acad Dermatol. 2001;44(4):593-598. (Pubitemid 32249513)
36. Nikolskaia OV, Nousari CH, Anhalt GJ. Paraneoplastic pemphigus in association with Castleman's disease. Br J Dermatol. 2003;149(6):1143-1151. (Pubitemid 38058089)
37. Maldonado F, Pittelkow MR, Ryu JH. Constrictive bronchiolitis associated with paraneoplastic autoimmune multi-organ syndrome. Respirology. 2009;14(1):129-133.
38. Mignogna MD, Fortuna G, Leuci S, Adamo D, Ruoppo E. Metastatic prostate cancer presenting as paraneoplastic pemphigus: a favourable clinical response to combined androgen blockade and conventional immunosuppressive therapy. Br J Dermatol. 2009;160(2):468-470.
39. Rybojad M, Leblanc T, Flageul B, et al. Paraneoplastic pemphigus in a child with a T-cell lymphoblastic lymphoma. Br J Dermatol. 1993;128(4):418-422. (Pubitemid 23105897)
40. Nassif A, Moslehi H, Le Gouvello S, et al. Evaluation of the potential role of cytokines in toxic epidermal necrolysis. J Invest Dermatol. 2004;123(5):850-855. (Pubitemid 39391928)
41. Murata J, Abe R, Shimizu H. Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment. J Allergy Clin Immunol. 2008;122(5):992-1000.
42. Probst C, Schlumberger W, Stöcker W, et al. Development of ELISA for the specific determination of autoantibodies against envoplakin and periplakin in paraneoplastic pemphigus. Clin Chim Acta. 2009;410(1-2):13-18.
43. Nagata Y, Karashima T, Watt FM, Salmhofer W, Kanzaki T, Hashimoto T. Paraneoplastic pemphigus sera react strongly with multiple epitopes on the various regions of envoplakin and periplakin, except for the c-terminal homologous domain of periplakin. J Invest Dermatol. 2001;116(4):556-563. (Pubitemid 32299845)